Building the Cannabinoid Supply Chain: Ireland’s Dunbar Pharma Decentralizes the Market

ATHLONE, Ireland – October 01, 2026

In a global economy increasingly defined by the resilience of its supply chains, Europe’s pharmaceutical infrastructure is undergoing a quiet but radical transformation. At the intersection of advanced manufacturing and decentralized healthcare, the professionalization of plant-derived medicines is reshaping how critical active pharmaceutical ingredients (APIs) are produced and distributed. Today, Dunbar Pharmaceuticals marked a significant milestone in this transition, announcing that its plant-derived WaterClear THC dronabinol API is now available to UK specialist prescribers in a new oral spray format.

Manufactured in partnership with IPS Pharma, a Medicines and Healthcare products Regulatory Agency (MHRA) licensed Specials manufacturer based in Surrey, the launch represents the UK’s first plant-derived dronabinol oral spray. The new dosage form joins the dronabinol capsules that were introduced to the UK market in August 2026, signaling a rapid expansion of finished pharmaceutical formats relying on Irish manufacturing infrastructure.

“The UK’s first plant-derived dronabinol oral spray is an important milestone for Dunbar,” said Leah Fletcher, co-founder and CEO of Dunbar Pharma. “With oral sprays alongside capsules, IPS Pharma is using our dronabinol API in a number of finished formats. That demonstrates the versatility of a defined, pharmaceutical-grade ingredient as we plan to expand production in 2027.”

The European Cannabinoid Corridor

The partnership between Dunbar Pharma and IPS Pharma highlights a growing cross-border commercial dynamic that is fortifying Europe's life sciences supply chain. Operating out of the Irish Midlands, Dunbar Pharma manufactures its WaterClear THC dronabinol API under strict EU Good Manufacturing Practice (GMP) certification. This certification, verifiable on the EudraGMDP public register, ensures that the plant-derived compounds meet rigorous, internationally recognized pharmacopoeia standards.

Once synthesized in Athlone, the API is exported under controlled-drug licenses to Surrey. There, IPS Pharma—a facility capable of producing over 20,000 formulations for unlicensed medicines—compounds the raw ingredient into patient-ready formats. This Athlone-to-Surrey corridor exemplifies a decentralized approach to pharmaceutical production, moving away from reliance on centralized, vulnerable supply nodes and toward a robust, European-based manufacturing network.

By applying stringent pharmaceutical quality standards to plant-derived cannabinoids, Dunbar is actively closing the gap between the rising global demand for medical cannabinoids and the historically lagging infrastructure required to produce them safely and consistently. Industry analysts note that this level of supply chain transparency and batch traceability is essential for maintaining dependable supply lines to licensed healthcare partners across Europe.

Financing Resilient Biopharma Infrastructure

The development of this advanced manufacturing base has not occurred in a vacuum. It is heavily supported by strategic capital aimed at building resilient domestic industries. Dunbar Pharma, operating corporately as Mercury Rising Ltd., is a High Potential Start-Up (HPSU) client of Enterprise Ireland. The Irish Government agency, alongside private domestic investors, has provided crucial backing to build out the company's GMP manufacturing operation.

This state-level investment underscores a broader economic strategy: securing competitive advantage by dominating highly regulated, difficult-to-manufacture life science niches. Employing 25 people in Ireland, Dunbar Pharma’s rapid ascent—recently recognized as the Emerging Company of the Year at the 2026 BioPharmaChem Impact Awards—demonstrates the viability of combining government backing with agile startup innovation to disrupt legacy pharmaceutical markets.

The capital injection has allowed Dunbar to pivot the medical cannabinoid sector away from the inconsistencies of early "gray market" supply chains. Instead, the company is establishing a foundation built on validated processes and Health Products Regulatory Authority (HPRA) oversight, ensuring that the financial and operational infrastructure matches the clinical demand.

Clinical Precision in the UK 'Specials' Market

For UK clinicians and patients, the commercial machinations in Ireland translate directly to expanded therapeutic options. In the UK, "Specials" are unlicensed medicines prescribed to meet the individual clinical needs of specific patients when no suitable licensed alternative is available. Navigating this pathway requires clinicians to adhere to strict General Medical Council (GMC) and National Institute for Health and Care Excellence (NICE) guidelines.

Historically, a major barrier to prescribing cannabis-based medicinal products (CBMPs) under the Specials framework has been inconsistent batch-to-batch quality. By utilizing a defined, EU GMP-certified API, the new oral spray mitigates these concerns, providing the standardized dosing that specialist doctors require to confidently manage chronic conditions.

Furthermore, the introduction of an oral spray formulation offers distinct clinical advantages over traditional oral capsules. Pharmacological data indicates that sublingual or buccal administration—where the spray is absorbed through the oral mucosa—can offer higher and more consistent bioavailability. Because this delivery method bypasses first-pass metabolism in the liver, patients often experience a faster onset of action. This rapid absorption is critical for patients requiring immediate symptom relief, while the spray format provides essential dosing flexibility for those who have difficulty swallowing capsules or require precise dose titration.

Scaling for Germany and the Decentralized Future

While the immediate focus is on equipping UK specialist prescribers, Dunbar Pharma’s strategic roadmap extends deep into the European continent. The company is actively working with partners on additional formulations, with a primary focus on the highly lucrative German market.

Germany represents a critical proving ground for pharmaceutical-grade cannabinoids. Recent market data reveals that the category including dronabinol accounted for more statutory health insurance prescriptions than cannabis flower in Germany in 2025. By entering this market earlier in 2026, Dunbar is positioning its plant-derived API against legacy synthetic dronabinol products, which have been prescribed since the 1980s but are often associated with slow absorption rates and high variability in patient response.

Dunbar’s 100% plant-derived approach offers a natural profile coupled with the rigorous purity of a pharmaceutical API. As the company plans to expand its manufacturing capacity at its Athlone site in 2027—and with further plant-derived active substances already in development—the infrastructure is being laid for a highly resilient, decentralized European supply chain. In a world where health and energy security are increasingly intertwined with domestic manufacturing capabilities, the professionalization of the cannabinoid market serves as a blueprint for the future of specialized medicine.